Seven orphan drugs including MSD’s sotatercept, for pulmonary arterial hypertension (PAH), and Pfizer's marstacimab, for patients with hemophilia, are among the latest products that have been filed for review by the European Medicines Agency for potential pan-EU marketing authorization.
Sotatercept is an investigational activin signaling inhibitor that, if approved, “would be the first in its class, bringing a novel...








